Pharma major Lupin today said the UK health regulator has completed inspection of its Goa facility without making any critical observations.
In a BSE filing, Lupin "announced the successful completion of the inspection by the UK MHRA at its Goa facility in March, 2018. There were no critical or major observations in the inspections".
"We are committed to maintaining truly global quality standards at our manufacturing units. The successful inspection by UK MHRA is a meaningful development for our Goa plant," Lupin Managing Director Nilesh Gupta said.
Yesterday, Lupin had announced that its Pithampur unit 2 manufacturing facility located in Indore had been cleared by Health Canada after a review.
In November 2017, Lupin had received warning letter from US Food and Drug Administration for its manufacturing facilities in Goa and Pithampur, Indore.
Shares of Lupin were trading 1.65 per cent higher at Rs 788.20 on BSE.
Disclaimer: No Business Standard Journalist was involved in creation of this content
